2. Disease Areas
  3. Urogenital Disease
  4. Female Reproductive System Disease
  5. Endometriosis

Endometriosis

Endometriosis is a chronic condition characterized by the presence of endometrial-like tissue outside the uterine cavity, commonly affecting the ovaries, fallopian tubes, peritoneum, and other pelvic organs, leading to inflammation, pain, adhesions, and infertility. It primarily impacts women of reproductive age, with a prevalence of 10% to 20% in the general population and up to 30% to 40% among infertile women. Key symptoms include severe dysmenorrhea, chronic pelvic pain, heavy menstrual bleeding, and difficulties with fertility, while some individuals may also experience bowel or urinary symptoms. The exact cause remains unknown, though hormonal, immunological, and genetic factors are believed to play a role. Diagnosis typically requires laparoscopy with histological confirmation. Although there is no cure, management strategies—such as hormonal therapy, pain relief, and surgical intervention—can help alleviate symptoms and improve quality of life.

References:

Endometriosis (10):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160645
    P2X4 antagonist-1 2055601-42-6 99.89%
    P2X4 antagonist-1 is a P2X4 receptor antagonist with an IC50 of 15 nM. P2X4 antagonist-1 inhibits ATP (HY-B2176)-induced calcium influx. P2X4 antagonist-1 can be used for the research of pain syndromes, endometriosis, cancer.
    P2X4 antagonist-1
  • HY-P992035
    AMY109
    AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with IC50 values of 0.14 μg/mL and 0.37 μg/mL against human IL-8, a Ka of 36.8 pM for human IL-8, and a Ka of 380 pM for cynomolgus monkey IL-8.\nAMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis.
    AMY109
  • HY-179528
    DIM-3,5-Cl2 2595179-74-9 99.18%
    DIM-3,5-Cl2 is an inverse NR4A1/NR4A2 agonist with KD values of 7.7 μM and 12.0 μM for NR4A1 and NR4A2, respectively. DIM-3,5-Cl2 acts as an inverse agonist to downregulate pro-oncogenic and proendometriotic gene products, and as an agonist to enhance NR4A1/2/Sp1/Sp4-mediated CD71 transactivation. DIM-3,5-Cl2 induces ferroptosis via ROS formation, lipoperoxidation, MDA production, and reduced GPX4, SLC7A11 expression. DIM-3,5-Cl2 induces apoptosis via PARP and caspase-3 cleavage, reduced BCL-2 expression, and inhibits cancer cell viability. DIM-3,5-Cl2 can be used for the research of triple negative breast cancer, endometriosis, and colorectal cancer.
    DIM-3,5-Cl2
  • HY-76737
    4-Chlorodiphenyl ether 7005-72-3
    4-Chlorodiphenyl ether (4-CDE) is an estrogen-mimicking active compound. 4-Chlorodiphenyl ether maintains the survival of endometriotic cysts and exhibits estrogenic activity associated with the growth of endometriotic implants. 4-Chlorodiphenyl ether can be used in research related to endometriosis.
    4-Chlorodiphenyl ether
  • HY-129791
    L-367773 152140-41-5
    L-367773 is an orally active, selective oxytocin receptor antagonist, with Ki values of 26 nM and 61 nM for rat uterine oxytocin receptor and human uterine oxytocin receptor, respectively. L-367773 inhibits Oxytocin-stimulated uterine contractions.
    L-367773
  • HY-182421
    GPR54 antagonist-1 925924-27-2
    GPR54 antagonist‑1 is a GPR54 antagonist with IC50 values of 3.6 nM and 15 nM against human and rat GPR54, respectively. GPR54 antagonist‑1 shows blood‑brain barrier penetration. GPR54 antagonist‑1 blocks the function of human and rat GPR54 receptors. GPR54 antagonist‑1 suppresses plasma luteinizing hormone levels in castrated male rats. GPR54 antagonist‑1 can be used for the study of prostate cancer and endometriosis.
    GPR54 antagonist-1
  • HY-119080
    CP8754 532435-68-0
    CP8754 is an orally active, selective human progesterone receptor (hPR) antagonist that blocks progesterone-mediated signaling pathways. CP8754 competitively inhibits the binding of [3H]-progesterone to hPR. And in vitro, CP8754 inhibits progesterone-dependent exogenous luciferase and endogenous alkaline phosphatase expression; while in vivo, CP8754 inhibits rabbit endometrial transformation. CP8754 does not significantly bind to human glucocorticoid receptors (hGR), estrogen receptors (hER), or rat androgen receptors (rAR). CP8754 can be used in the study of progesterone-related diseases such as breast cancer, endometriosis, uterine fibroids, and meningioma, as well as hormone-dependent tumors.
    CP8754
  • HY-156701
    BAY-1128688 1428988-21-9
    BAY-1128688 is a potent, orally active and selective AKR1C3 inhibitor with IC50 < 2 nM. BAY-1128688 shows high selectivity over related AKR1C enzymes (1C1, 1C2, 1C4) and AKR1D1. BAY-1128688 exhibits no relevant activity at major nuclear hormone receptors. BAY-1128688 reduces endometriotic lesions in the marmoset monkey endometriosis model. BAY-1128688 can be used for endometriosis research.
    BAY-1128688
  • HY-76737S
    4-Chlorodiphenyl ether-d5 93951-85-0 99.3%
    4-Chlorodiphenyl ether-d5 (4-CDE-d5) is the deuterium labeled 4-Chlorodiphenyl ether. 4-Chlorodiphenyl ether is an estrogen-mimicking active compound. 4-Chlorodiphenyl ether maintains the survival of endometriotic cysts and exhibits estrogenic activity associated with the growth of endometriotic implants. 4-Chlorodiphenyl ether can be used in research related to endometriosis.
    4-Chlorodiphenyl ether-d<sub>5</sub>
  • HY-181637
    4-DMA-3'-OH-Chalcone 946437-21-4
    4-DMA-3'-OH-Chalcone (compound 24) is a synthetic chalcone derivative and selective cytotoxic agent.4-DMA-3'-OH-Chalcone reduces viability of endometriotic cells, while preserving or enhancing viability of eutopic endometrial cells.4-DMA-3'-OH-Chalcone can be used for the research of endometriosis.
    4-DMA-3'-OH-Chalcone